Week 4 CML Flashcards
Wnt-b catenin
When activated GMP can self renewal
leads to accelerated and blast phase
CEBPalpha
when inhibited, leads to differentiation block found in accelerated and blast phase
Creation of BCR-ABL
abl1 from 9 swaps with segment of 22 and attaches to BCR portion of 9. makes philly chromosome
TRANSLOCATION
BCR-ABL1 mechanism
Lacks myristate, leaving it in open position (active)
Coiled coil region of BCR promotes dimerization (needed for tyrosine kinase)
Result is no signal needed to activate
Y177 in CML
Binds to BCR-ABL1 complex and is phosphorylated
Leads to dysregulated prolif and protection against apoptosis
Not normally activated by BCR because BCR is not tyrosine kinase
Stat5 in CML
Phosphorylated without control, leads to proliferation
Imatinib mechanism
Binds ATP site on bcr-abl1 complex and shuts it down.
Cure for CML?
Imatinib has 85-95% response. delays death in 25% of blast crisis
bone marrow transplant only curative therpay. (cant get over age 60)
chronic myeloid leukemia
CMPD
neutrophils
increase WBC. Left shift. basophilia
low hemo AND high platelet (at first)
Sx - fever fatigue and night sweats. abd fullness
signs - big spleen and liver
polychythemia vera
CMPD
^RBC. Need to be from myeloid problem, not kidney
Thrombosis and hemorrhage
Jak-2 mutation (cells grown on their own). Phospho receptor, stat attaches, phospho stat, dimer goes to transcription
Sx - plethora (flushing) and big liver/spleen
Signs - headache, thrombosis, infarct
essential thromobcythemia
CMPD
Platelets (can happen in young women)
thrombosis and hemorrhage
diagnose by ruling everything else out and platelet over 600K
sx: bleeding and thrombosis
signs: bruising, pallor, large spleen, tachycardic
myelofibrosis
CMPD chronic myeloproliferative disorder
Everything prolif! Panyelosis and eventually marrow fibrosis
extramedullary hematopoiesis and tear drop cells
Sx: LUQ fullness, weakness, fatigue, heat arrythmia
signs: large spleen/liver and pallor, tachycardia
treatment for polychythemia vera
phlebotomy. maybe suppressive drugs
9-14 years average but die form thrombosis or hemorrhage
treatment for essential thrombocythemia
platelet pheresis, suppressive drugs and aspirin
5-8 years, but die from thrombosis or hemorrhage
treatment for myelofibrosis
supportive
3-5years but die from marrow failure